Research, Select, & Monitor Sunday, June 17, 2018 6:31:10 PM ET  
Trade Ideas The Market Industries Stocks Portfolio

Ticker Lookup
Valeant Pharmaceuticals International, Inc.$26.86$.06.22%

  Quote | Ranking | Chart | Valuations | Sentiment | News | Earnings | Analysts | More...

Your Target?

  Valeant Pharmaceuticals International, Inc. vs Drug Delivery

Valeant Pharmaceuticals International, Inc. is a pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics. The Company produces medicines that meet the special health problems of patients. Valeant's development pipeline strategy comprises both new compounds as well as product life cycle management. Its early and late-stage drug candidates have unique formulations and mechanisms of action including retigabine for the treatment of epilepsy and pain, taribavirin of the treatment of chronic hepatitis C, and several dermatology candidates for the treatment of rosacea, acne, and dermatological fungus. Valeant Pharmaceuticals International, Inc. is headquartered in Mississauga, Canada.

Innovative companies whose purpose is to design and develop new ways to introduce drugs to the body. These new methods may consist of time-released capsules, differing injection techniques, or enabling certain drugs to be taken orally that may not have been to be taken so before. Their revenue is obtained from selling their technology to pharmaceutical companies or licensing it to manufacturers of prescription drugs.
 Totals Company Industry
  Sales: $8,724.0 Mil $119,469.6 Mil
  Market Cap: $9,418.5 Mil $343,504.9 Mil
  Analysts Recommendation: Buy Buy

 Averages Company Industry
  Historic Revenue: (9.8%) 17.8%
  Estimated Revenue: (5.0%) 37.9%
  Historic Earnings: (30.0%) 79.9%
  Estimated Earnings: (3.8%) 18.4%
  Stock Price (1 Year): 121.6% 84.0%
  Cash per Share: 46.7% (7.5%)
  Dividend: N/A N/A
  Trailing PE: N/A N/A
  Forward PE: 7.6 18.7
  Price-to-Sales: 1.1 N/A
  Price-to-Book: 1.6 7.8
  Dividend Yield: N/A N/A
  Market Cap: $9,418.5 Mil $22,900.3 Mil
  Net Margin: 16.1% (135.6%)
  Gross Margin: 70.8% 74.6%
  Return on Equity: .4 (.4)
  Return on Assets: .1 (.2)
  Balance Sheet
  Current Ratio: 1.1 2.1
  Quick Ratio: .9 1.8
  Cash Ratio: .2 1.3
  Debt-to-Equity: 5.3 3.9
  Interest Coverage: (.0) .1
  Relative-Strength Index: 84.3 N/A

 Other companies in Drug Delivery Price Market Cap
  Roche Holding AG  (RHHBY) $26.64 $181,562.8 Mil
  Sanofi  (SNY) $39.94 $99,706.2 Mil
  Eisai Co Ltd  (ESALY) $73.27 $21,729.7 Mil
  Nektar Therapeutics  (NKTR) $57.86 $9,308.7 Mil
  Alkermes, Inc.  (ALKS) $50.30 $7,767.5 Mil

Register |  Password |  Feedback |  Copyright |  Usage Agreement |  Privacy Policy |  Advertising |  About Us |  Contact Us |  FAQ 

Past performance is not indicative of future results, the logo, and News Selects are trademarks of
Copyright © 1998 - 2018 All rights reserved.